drugset / Trial / NCT01656265
Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dose of ARQ 197 in advanced HCC patients.
Timeline
- Start
- 2012-07
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | — | Oral |